Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CE-326, 597 · 2 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| CE-326,597 100 mg QD | EXPERIMENTAL | - |
| CE-326,597 50 mg QD | EXPERIMENTAL | - |
| CE-326,597 25 mg QD | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| CE-326,597 5mg QD | EXPERIMENTAL | - |
| CE-326,597 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| CE-326,597 100 mg QD | DRUG | Administered orally, once daily with morning meal for duration of trial (84 days). |
| CE-326,597 50 mg QD | DRUG | Administered orally, once daily with morning meal for duration of trial (84 days). |
| CE-326,597 25 mg QD | DRUG | Administered orally, once daily with morning meal for duration of trial (84 days). |
| Placebo | DRUG | Placebo to match CE-326,597 tablets to be administered orally, once daily with morning meal for duration of trial (84 days). |
| CE-326,597 5mg QD | DRUG | Administered orally, once daily with morning meal for duration of trial (84 days). |
| CE-326,597 | DRUG | CE-326,597 administered orally, once daily for 14-days at 1 to 2 doses (25 mg QD, 100 mg QD) with the morning meal. |
Inclusion Criteria: Patients with type 2 diabetes, not on any or on oral (up to 2) anti-diabetic medications, otherwise medically stable. Exclusion Criteria: Women of childbearing potential, people with unstable medical conditions, people with gallstones
CE-326,597 was studied for obesity and weight management. It is a small molecule developed by Pfizer, Inc. as an investigational treatment for weight management and treatment of obesity. It has been tested in patients with obesity and in diabetic patients to assess effects on glucose control and body weight.
CE-326,597 is developed by Pfizer, Inc., which trades under the ticker PFE. Pfizer conducted the clinical trials of CE-326,597, including a Phase 1 study in patients with asymptomatic gallstones and a Phase 2 trial in diabetic patients.
CE-326,597 has completed a Phase 1 trial and a Phase 2 trial. The Phase 1 study evaluated safety and pharmacokinetics in patients with asymptomatic gallstones, while the Phase 2 trial assessed effects on glucose control and body weight in diabetic patients. No active trials are currently listed.
CE-326,597 has been studied in two completed trials: NCT00576589, a Phase 1 study of safety and pharmacokinetics in patients with asymptomatic gallstones, and NCT00542009, a Phase 2 trial in diabetic patients to assess effects on glucose control and body weight. Both trials are completed.